Protocol Details
Biospecimen Acquisition from Human Subjects
This study is currently recruiting participants.
Summary
Number | 02-C-0179 |
Sponsoring Institute | National Cancer Institute (NCI) |
Recruitment Detail | Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A |
Referral Letter Required | No |
Population Exclusion(s) | Children;
Adults who are or may become unable to consent;
Pregnant Women;
Fetuses;
Neonates |
Keywords | Suppressor Cells;
T-cells;
CD4+ / CD25+ cells;
Natural History |
Recruitment Keyword(s) | Cancer;
Malignancy;
Blood Sample |
Condition(s) | Prostate Cancer;
Breast Cancer;
Colon Cancer;
Lung Cancer;
Liver Cancer |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Cancer Institute |
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients
18 years of age and older with cancer may participate. This study does not involve treatment.
Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.
Eligibility
INCLUSION CRITERIA:
Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible.
Performance status of ECOG 0, 1, 2, or 3 for admission to this protocol.
Ability to understand and the willingness to sign a written informed consent document.
INCLUSION FOR APHERESIS:
Note: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference.
Hemoglobin greater than or equal to 10 mg/dL and platelet count > 75,000/mm(3)
Weight greater than 25 kg
HIV negative
Prothrombin Time - within normal limits
Partial Thromboplastin Time - within normal limits
Medically indicated central line in place or adequate peripheral venous access
EXCLUSION CRITERIA:
None.
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT00034216